Excellent
Fully Aligned
Patient Risk:
Low
Summary
The response’s sole substantive claim—that Balcoltra is contraindicated in women over 35 who smoke due to increased risk of serious cardiovascular events—is directly and explicitly supported by the label’s Boxed Warning, Contraindications, Warnings (5.1), and Patient Counseling (17), with no contradictions identified.
Category Scores
Accurate Statements
Balcoltra is contraindicated in women over 35 who smoke due to increased risk of serious cardiovascular events (e.g., stroke/MI).
Supported by Boxed Warning (smoking increases serious cardiovascular events; risk increases with age/number of cigarettes; COCs contraindicated in women >35 who smoke) and reiterated in Contraindications (smoke if over age 35), with additional supporting language in Warnings (5.1) regarding arterial thromboses including strokes and myocardial infarctions and increased risk in women >35 who smoke; also reinforced in Patient Counseling (17) stating women >35 who smoke should not use COCs.
Unsupported Statements
Contradictions
Important Omissions
No additional omissions identified relative to the specific claim evaluated (smoking/age contraindication).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The statement evaluated is an explicit contraindication supported by the FDA label; no unsafe or contradictory information was introduced.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement